-- Gilead Sciences K.K. is Now Marketing Authorization Holder --
-- Kite Cell Therapy Business Unit of Gilead Sciences K.K. will manage the product's sales and promotion activities --
-- Kite's
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company